**OBJECTIVES**

- Eligible patients were male or female, aged ≥18 years; had a pathologic diagnosis of R/R DLBCL or ≥1 prior therapy; and had an Eastern Cooperative Oncology Group performance status of 0–2.
- Patients previously treated with Lonca or ibrutinib or other Bruton’s tyrosine kinase inhibitors were excluded from the study.

**CONCLUSIONS**

- Eight (21.6%) patients were primary refractory and 12 (32.4%) patients were secondary refractory.
- Response is ongoing in 4/24 patients with non-GCB DLBCL and 3/7 patients with MCL (Figure 3).

**METHODS**

- Clinical activity of loncastuximab tesirine plus ibrutinib in non-Hodgkin lymphoma: Updated LOTIS-3 Phase 1 results

**RESULTS**

- Patient demographics and baseline characteristics
- Summary of PK parameters

**CONCLUSIONS**

- Lonca 60 µg/kg plus ibrutinib 560 mg had encouraging antitumor activity in RIR DLBCL or RIR MCL, with an ORR of 62.2%.
- ORR for non-GCB DLBCL was 66.7%, GCB DLBCL was 16.7%, and MCL was 85.7%.
- PK profiles exhibit sustained exposure and modest accumulation with the CLIN regimen by Cycle 2.

**ACKNOWLEDGMENTS**

- The authors received editorial/writing support in the preparation of this poster provided by Sarah Meadows of ADC Therapeutics America, Inc. (Murray Hill, NJ, USA)